BlackRock, Inc. 13D and 13G filings for Poseida Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-08 2:17 pm Unchanged |
2024-09-30 | 13G | Poseida Therapeutics, Inc. PSTX |
BlackRock Inc. BLK |
5,123,969 5.300% |
0 (Unchanged) |
Filing |
| 2024-10-22 3:24 pm Purchase |
2024-09-30 | 13G | Poseida Therapeutics, Inc. PSTX |
BlackRock Inc. BLK |
5,123,969 5.300% |
296,730 (+6.15%) |
Filing |
| 2024-06-07 1:30 pm Sale |
2024-05-31 | 13G | Poseida Therapeutics, Inc. PSTX |
BlackRock Inc. BLK |
4,827,239 4.970% |
-203,934 (-4.05%) |
Filing |
| 2024-01-31 2:08 pm Purchase |
2023-12-31 | 13G | Poseida Therapeutics, Inc. PSTX |
BlackRock Inc. BLK |
5,031,173 5.300% |
5,031,173 (New Position) |
Filing |